Immunophenotyping of lymphocyte T and B in the peripheral blood of systemic lupus erythematosus

Abstract

The immunophenotyping expression levels of lymphocyte in the peripheral blood from 21 patients with active systemic lupus erythematosus (SLE) were analyzed by using the immunofluorescence labeling-flow cytometry technique to investigate the immunophenotyping expression of lymphocytes T and B in the peripheral blood of active SLE patients and its clinical value. It was showed that, compared with normal controls, the expression of CD₃⁺, CD₄⁺ and the ratio of CD₄⁺/CD₈⁺ in the peripheral blood of these patients were decreased (P< 0. 01), while the expression of CD₈⁺, CD₂₀⁺ was significantly increased (P< 0. 01). It was suggested that both T and B cells in patients with active SLE involved in immunoregulation, were activated. The abnormal expression of lymphocyte immunophenotyping could influence the immune reaction in SLE patients, which might be one of the important pathogenesis factors in SLE.

Keywords

systemic lupus erythematosus / immunophenotyping

References

[1] MatthewH, StevenA, MartinG, et al.. Reliability and validity of six systemic for the clinical assessment of six systems of disease activity in systemic lupus erythematosus. Arthritis Rheum, 1989, 32: 1107-1107

[2] GlaireB, DafnaD, GladmanM, et al.. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-630

[3] ShigemasaS, HitamaJ, MiemazeS, et al.. Soluble CD4/ CD8 molecules in rheumatic disorders. Clin Immun and Immunopathol, 1994, 72(2): 177-177

[4] LiossisS N, HoffmanR W, TsokosG C. Abnormal early TCR/CD3-mediated signaling events of a snRNP-autoreactive lupus T cell clone. Clin Immunol Immunopathol, 1998, 88(3): 305-305

[5] OootoY, IkemotoT, NakagawaT, et al.. Quantitative flowcytometric analysis of B cell surface antigens in patients with autoimmune diseases. Rinsho Byori, 1995, 43(4): 381-381

[6] SpronkP E, HorstG, Van Der GunB T, et al.. Anti-ds-DNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol, 1996, 104(3): 446-446